CYT006-AngQb

BIOLOGICAL3 trials

Sponsors

Cytos Biotechnology AG

Conditions

Essential HypertensionHypertensionMild Essential HypertensionModerate Essential Hypertension

Phase 1

Safety, Tolerability, Pharmacodynamic Effects and Preliminary Evidence for Efficacy of the Anti-Hypertension Vaccine CYT006-AngQb

CompletedNCT00500786

Cytos Biotechnology AGEssential Hypertension

Start: 2004-11-30End: 2007-04-30Updated: 2012-08-21

Phase 2

Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of a Vaccine Against Essential Hypertension

CompletedNCT00701649

Cytos Biotechnology AGHypertension

Start: 2008-03-31End: 2009-11-30Target: 60Updated: 2009-12-02

Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension

CompletedNCT00710372

Cytos Biotechnology AGMild Essential Hypertension, Moderate Essential Hypertension

Start: 2008-06-30End: 2010-11-30Updated: 2010-11-15

Related Papers

Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study.

2008-03-01187 citations